Inhibitors in Hemophilia B

Area of Science:

• Hematology
• Immunology
• Genetics

Background:

• Hemophilia B (HB) is an X-linked disorder due to factor IX (FIX) deficiency.
• Severe HB (FIX <1%) leads to recurrent bleeds; prophylactic regimens have improved outcomes.
• FIX inhibitors are now a major complication, despite reduced viral risks and arthropathy.

Purpose of the Study:

• To review current knowledge on risk factors, pathophysiology, and clinical aspects of FIX inhibitors in Hemophilia B.
• To highlight the challenges and developing strategies for managing this rare complication.

Main Methods:

• This is a narrative review.
• Literature search on risk factors, pathophysiology, and clinical presentation of FIX inhibitors in HB.
• Discussion of current and developing therapeutic strategies.

Main Results:

• FIX inhibitors are rare (1.5-3%) but cause significant morbidity, including bleeding and allergic reactions.
• Inducing immune tolerance is often unsuccessful and complicated by allergies.
• Limited data exist on risk factors and pathophysiology due to the rarity of the event.

Conclusions:

• FIX inhibitors represent a critical challenge in Hemophilia B management.
• Further research into risk factors, pathophysiology, and novel therapies is crucial.
• Alternative strategies are needed due to the limitations of immune tolerance induction.